Medulloblastoma

Neuro-Oncology of CNS Tumors

Volumn , Issue , 2006, Pages 461-469

  Taylor, Michael D ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892324904     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/3-540-31260-9_35     Document Type: Chapter

References (22)

1. Rutka JT. Medulloblastoma. Clin Neurosurg 1997;44: 571-585
2. Mitchell D, Rojiani AM, Richards D, Yachnis AT, Powell SZ. Congenital CNS primitive neuroectodermal tumor: case report and review of the literature. Pediatr Pathol Lab Med 1995;15:949-956
3. Rutka JT, Hoffman HJ. Medulloblastoma: a historical perspective and overview. J Neurooncol 1996;29:1-7
4. Wechsler-Reya R, Scott MP. The developmental biology of brain tumors. Annu Rev Neurosci 2001;24:385-428
5. Sutton LN, Phillips PC, Molloy PT. Surgical management of medulloblastoma. J Neurooncol 1996;29:9-21
6. Park TS, Hoffman HJ, Hendrick EB, Humphreys RP, Becker LE. Medulloblastoma: clinical presentation and management. Experience at the hospital for sick children. Toronto, 1950-1980. J Neurosurg 1983;58:543-552
7. Giangaspero F, Perilongo G, Fondelli MP, Brisigotti M, Car-olio C, Burnelli R, et al. Medulloblastoma with extensive nodularity: a variant with favorable prognosis. J Neurosurg 1999;91:971-977
8. Packer RJ, Biegel JA, Blaney S, Finlay J, Geyer JR, Heide-man R, et al. Atypical teratoid/rhabdoid tumor of the central nervous system: report on workshop. J Pediatr Hema-tol Oncol 2002;24:337-342
9. Biegel JA, Zhou JY, Rorke LB, Stenstrom C, Wainwright LM, Fogelgren B. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res 1999;59:74-79
10. Frank AJ, Hernan R, Hollander A, Lindsey JC, Lusher ME, Fuller CE, et al. The TP53-ARF tumor suppressor pathway is frequently disrupted in large/cell anaplastic medulloblastoma. Brain Res Mol Brain Res 2004;121:137-140
11. Bayani J, Zielenska M, Marrano P, Kwan Ng Y, Taylor MD, Jay V, et al. Molecular cytogenetic analysis of medulloblas-tomas and supratentorial primitive neuroectodermal tumors by using conventional banding, comparative genomic hybridization, and spectral karyotyping. J Neurosurg 2000;93:437-448
12. Taylor MD, Mainprize TG, Rutka JT. Molecular insight into medulloblastoma and central nervous system primitive neuroectodermal tumor biology from hereditary syndromes: a review. Neurosurgery 2000;47:888-901
13. Taylor MD, Liu L, Raffel C, Hui CC, Mainprize TG, Zhang X, et al. Mutations in SUFU predispose to medulloblastoma. Nat Genet 2002;31:306-310
14. Hamilton SR, Liu B, Parsons RE, Papadopoulos N, Jen J, Powell SM, et al. The molecular basis of Turcot's syndrome. N Engl J Med 1995;332:839-847
15. Pollack IF, Polinko P, Albright AL, Towbin R, Fitz C. Mutism and pseudobulbar symptoms after resection of posterior fossa tumors in children: incidence and pathophysiology. Neurosurgery 1995;37:885-893
16. Mulhern RK, Merchant TE, Gajjar A, Reddick WE, Kun LE. Late neurocognitive sequelae in survivors of brain tumours in childhood. Lancet Oncol 2004;5:399-408
17. Rood BR, Macdonald TJ, Packer RJ. Current treatment of medulloblastoma: recent advances and future challenges. Semin Oncol 2004;31:666-675
18. Mason WP, Grovas A, Halpern S, Dunkel IJ, Garvin J, Heller G, et al. Intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors. J Clin Oncol 1998;16:210-221
19. Cohen BH, Packer RJ. Chemotherapy for medulloblasto-mas and primitive neuroectodermal tumors. J Neuroon-col 1996;29:55-68
20. Gajjar A, Hernan R, Kocak M, Fuller C, Lee Y, McKinnon PJ, et al. Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J Clin Oncol 2004;22:984-993
21. Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME, et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 2002;415:436-442
22. Romer JT, Kimura H, Magdaleno S, Sasai K, Fuller C, Baines H, et al. Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptcl(+/-)p53(-/-) mice. Cancer Cell 2004;6:229-240